This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Aficamten in Hypertrophic Cardiomyopathy: ACACIA-HCM, ODYSSEY-HCM, and MAPLE-HCM Trial Perspectives

Ticker(s): CYTK, BMY

Who's the expert?

Institution: The Christ Hospital

  • Advanced Heart Failure & Transplant Cardiologist at The Christ Hospital in Cinncinnati, OH

  • Manages 500+ patients with Hypertrophic Cardiomyopathy

  • Co-Director of the Hypertrophic Cardiomyopathy Clinic and serves as a Principal Investigator on numerous HCM-related trials

Interview Questions
Q1.

How many patients do you manage with oHCM?

Added By: lilly_admin
Q2.

On a scale from 1-10 (10 being extremely excited), where would you rate your level of excitement for Aficamten as a treatment for oHCM?

Added By: lilly_admin
Q3.

What are your thoughts about the likelihood of success for CYTK’s ACACIA trial in non-obstructive HCM given the BMY ODYSSEY data at ESC?

Added By: lilly_admin
Q4.

If Aficamten becomes available and the ACACIA trial's safety and efficacy read positively, what percentage of your patients would you consider prescribing it to?

Added By: user9110913b

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.